Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Comparison of Bone Mineral Density in the Third Trimester Between Women in Singleton and Twin Pregnancies Using Questionnaires and REMS Densitometric Examination

Pregnancy-associated Reduction in Bone Mineral Density: a Comparative Study Using REMS Technology Between Singleton and Twin Pregnancies in the Third Trimester

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This clinical study aims to monitor and evaluate bone mineral density and fracture risk in women with singleton and twin pregnancies through the combined use of: * two specific questionnaires developed by the Fragility Fracture Observatory (OFF), and * a bone densitometric examination using REMS technology, performed between the 35th and 41st week of gestation. Primary objective: • To identify, in the third trimester of pregnancy (between the 35th and 41st gestational week), any differences in bone mineral density (BMD) between women with singleton pregnancies and women with dichorionic and monochorionic twin pregnancies. Secondary objectives: * Evaluate the relationship between bone mineral density (BMD) values and maternal clinical and historical parameters, such as age, body mass index (BMI), and obstetric and medical history. * Evaluate the association between BMD values and scores obtained from validated questionnaires administered to investigate fracture risk and bone health-related quality of life in women with singleton and twin pregnancies.

Who May Be Eligible (Plain English)

INCLUSION CRITERIA 1. Signed willing to sign a consent form 2. Willingness to participate in the study and ability to complete the study questionnaires 3. Women between 35 and 41 weeks of gestational age at the time of study inclusion 4. Singleton or twin pregnancy (dichorionic or monochorionic) 5. Age between 30 and 45 years at the time of study recruitment 6. No history of recent or previous bone fractures or traumatic fractures, and no motor disabilities (in the mother). 7. Absence of a diagnosis of osteopenia or osteoporosis according to the criteria of the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS). 8. No intake of vitamin D or other medications during pregnancy. 9. Absence of current or previous conditions that could potentially interfere with bone metabolism (e.g., thyroid, kidney, or liver disease). 10. Women of normal weight or with class I obesity (BMI between 18.5 and 34). EXCLUSION CRITERIA Patients will not be included in the study if at least one of the following exclusion criteria is met: 1. Failure to sign the willing to sign a consent form form 2. Poor compliance and/or inability to complete the study questionnaires 3. Women with previous or newly diagnosed comorbidities during pregnancy 4. Age \<30 and \>45 years 5. Previous diagnosis of osteopenia or osteoporosis according to the criteria of the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS) 6. BMI \<18.5 or \>34 Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
INCLUSION CRITERIA 1. Signed informed consent 2. Willingness to participate in the study and ability to complete the study questionnaires 3. Women between 35 and 41 weeks of gestational age at the time of study inclusion 4. Singleton or twin pregnancy (dichorionic or monochorionic) 5. Age between 30 and 45 years at the time of study recruitment 6. No history of recent or previous bone fractures or traumatic fractures, and no motor disabilities (in the mother). 7. Absence of a diagnosis of osteopenia or osteoporosis according to the criteria of the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS). 8. No intake of vitamin D or other medications during pregnancy. 9. Absence of current or previous conditions that could potentially interfere with bone metabolism (e.g., thyroid, kidney, or liver disease). 10. Women of normal weight or with class I obesity (BMI between 18.5 and 34). EXCLUSION CRITERIA Patients will not be included in the study if at least one of the following exclusion criteria is met: 1. Failure to sign the informed consent form 2. Poor compliance and/or inability to complete the study questionnaires 3. Women with previous or newly diagnosed comorbidities during pregnancy 4. Age \<30 and \>45 years 5. Previous diagnosis of osteopenia or osteoporosis according to the criteria of the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS) 6. BMI \<18.5 or \>34

Treatments Being Tested

DEVICE

bone densitometric examination using REMS technology

An assessment of bone health using ultrasound densitometry using REMS technology, integrated into the EchoStation device (Echolight Spa, Lecce, Italy), is performed during the third trimester check-up. Thanks to an innovative parameter called Fragility Score (FS), intrinsically correlated with bone quality and independent of BMD, REMS allows assessment of bone fragility and its resulting fracture risk, representing a useful diagnostic tool also in predicting the risk of fragility fractures.

OTHER

questionnaires

Specific questionnaires developed by the Fragility Fracture Observatory (OFF) will be administered. Their purpose is to assess all risk factors that could lead to fractures during pregnancy, as well as to evaluate both dietary habits and adherence to the Mediterranean diet

Locations (1)

Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, RM, Italy